Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral clearance 92% Improvement Relative Risk Recovery 77% Recovery time 85% no CI Recovery time (b) 81% no CI Cadegiani et al. Proxalutamide for COVID-19 RCT EARLY Is early treatment with antiandrogens beneficial for COVID-19? Double-blind RCT 237 patients in Brazil Improved viral clearance (p<0.0001) and recovery (p<0.0001) Cadegiani et al., Cureus, doi:10.7759/cureus.13492 Favors proxalutamide Favors control
Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Cadegiani et al., Cureus, doi:10.7759/cureus.13492
Cadegiani et al., Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients.., Cureus, doi:10.7759/cureus.13492
Feb 2021   Source   PDF  
  All Studies   Meta
RCT 234 mild-moderate COVID-19 patients with 171 treated with proxalutamide, showing significantly faster viral clearance and recovery. Third party analysis suggests potential randomization failure: []. This study is excluded in meta analysis: potential randomization failure.
risk of no viral clearance, 92.1% lower, RR 0.08, p < 0.001, treatment 7 of 171 (4.1%), control 34 of 66 (51.5%), NNT 2.1, day 7, not including loss of taste or smell.
risk of no recovery, 76.8% lower, RR 0.23, p < 0.001, treatment 30 of 171 (17.5%), control 50 of 66 (75.8%), NNT 1.7, day 7, including loss of taste or smell.
recovery time, 85.0% lower, relative time 0.15, treatment 171, control 66, day 7, not including loss of taste or smell.
recovery time, 80.7% lower, relative time 0.19, treatment 171, control 66, day 7, including loss of taste or smell.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cadegiani et al., 22 Feb 2021, Double Blind Randomized Controlled Trial, Brazil, peer-reviewed, 8 authors, average treatment delay 4.2 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: Open Access Original Article DOI: 10.7759/cureus.13492 Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, DoubleBlinded, Placebo-Controlled Trial Flavio A. Cadegiani 1, 2 , John McCoy 3 , Carlos Gustavo Wambier 4 , Sergio Vaño-Galván 5 , Jerry Shapiro 6 , Antonella Tosti 7 , Ricardo A. Zimerman 8 , Andy Goren 9 1. Internal Medicine: Diabetes and Endocrinology, Applied Biology Inc, Irvine, USA 2. Clinical Endocrinology, Federal University of São Paulo, São Paulo, BRA 3. Research & Development, Applied Biology Inc, Irvine, USA 4. Dermatology, The Alpert Medical School of Brown University, Providence, USA 5. Dermatology, Ramon y Cajal Hospital, Madrid, ESP 6. Ronald O. Perelman Department of Dermatology, New York University, New York, USA 7. Dermatology, University of Miami Health System, Miami, USA 8. Infectious Diseases, Hospital da Brigada Militar, Porto Alegre, BRA 9. Dermatology, Applied Biology Inc, Irvine, USA Corresponding author: John McCoy, Abstract Background The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into type II pneumocytes is dependent on a modification of viral spike proteins by transmembrane protease serine 2 (TMPRSS2) expressed on the surface of human cells. TMPRSS2 is regulated by the androgen receptor, hence, SARS-CoV2 infectivity is indirectly dependent on androgenic status and phenotype. Previously, we have reported that men affected by androgenetic alopecia (AGA) are overrepresented in severe coronavirus disease 2019 (COVID-19). Additionally, we have reported that men taking antiandrogenic drugs, e.g., 5-alpha-reductase inhibitors (5ARis), are less likely to have severe COVID-19. Here we aimed to test whether the androgen receptor antagonist, Proxalutamide, would be a beneficial treatment for subjects with SARS-CoV-2 infection. Methods Male and female subjects were recruited to a double-blinded, randomized, prospective, investigational study of Proxalutamide for the treatment of COVID-19. Mild to moderate, non-hospitalized subjects, who were confirmed positive for SARS-CoV-2, were treated with either Proxalutamide 200 mg/day or placebo. Endpoints for the study were remission time (days) and the percentage of subjects confirmed negative for SARS-CoV-2 on Day 7 after treatment. A negative SARS-CoV-2 test was defined by concentration-time (Ct)>40 determined by real-time reverse transcription-polymerase chain reaction (rtPCR). Review began 02/04/2021 Results Review ended 02/15/2021 Published 02/22/2021 © Copyright 2021 Cadegiani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted Two-hundred thirty-six (2360 subjects were included in the study (108 female, 128 male); 171 were randomized to the Proxalutamide arm and 65 were in the placebo group. On Day 7, SARS-CoV-2 became non-detectable with rtPCR (cT>40) in 82% of the subjects in the Proxalutamide group versus 31% in the placebo group (p < 0.001). The average clinical remission time for patients treated with Proxalutamide was 4.2 ±5.4 days versus 21.8 ±13.0 days in the placebo arm (p < 0.001). use, distribution, and reproduction in any medium, provided the original author and source are credited. Conclusion Proxalutamide significantly accelerated viral clearance on Day 7 in mild to moderate COVID-19..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop